GSK wins jury verdict in Illinois ranitidine cancer case

GSK

GSK plc has welcomed today’s jury verdict in the Joiner case in Illinois state court finding in GSK’s favour.

·   Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer

·   Verdict is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

·   GSK will continue to vigorously defend itself against all other claims

This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims.

Prior to this verdict, the court rejected the Plaintiff’s ability to request punitive damages.

Share on:

Latest Company News

GSK subsidiary TESARO starts legal action over Jemperli licence dispute

TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.

GSK receives EMA Orphan Drug Designation for GSK5764227 in Pulmonary NEC

GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer.

GSK Plc gains FDA approval for Blenrep combination in multiple myeloma

GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies.

GSK Plc names Luke Miels as CEO Designate, effective January 2026

GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis.

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over.

    Search

    Search